Proper use of antiarrhythmic therapy for reduction of mortality after myocardial infarction

Drugs and Aging

Volumn 16, Issue 5, 2000, Pages 341-350

  Larsen, Jennifer A ^a   Kadish, Alan H ^a   Schwartz, Janice B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; IMIPRAMINE; LIDOCAINE; LIDOFLAZINE; LORCAINIDE; MEXILETINE; MORACIZINE; NIFEDIPINE; PHENYTOIN; PIRMENOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TIAPAMIL; TIMOLOL; TOCAINIDE; VERAPAMIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG CHOICE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART INFARCTION; HUMAN; IMPLANTATION; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

EID: 0034038774     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016050-00004     Document Type: Review

References (47)

1. 1. Lown B, Klein MD, Hershberg PI. Coronary and pre-coronary care. Am J Med 1969; 46: 705-24
2. 2. Lawrie DM, Higgins MR, Godman MJ, et al. Ventricular fibrillation complicating acute myocardial infarction. Lancet 1968; 2: 523-8
3. 3. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature heats and mortality after myocardial infarction. N Engl J Med 1977; 297: 750-7
4. 4. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-6
5. 5. Moss AJ, Davis HT, DeCamilla J, et al. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1979; 60 (5): 998-1003
6. 6. Vaughan Williams EM. Classification of anti-arrhythmic drugs. In: Sandoe E, Flensted-Jansen E, Olesen KH, editors. Symposium on cardiac arrhythmias, Södertalje, Sweden: AB Astra, 1970: 449-472
7. 7. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-47
8. 8. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 1983; 52: 32-6C
9. 9. Yusef S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, treatments following myocardial infarction. JAMA 1988; 260: 2088-93
10. 10. Hine LK, Laird NM, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037-40
11. 11. Teo KK, Yusef S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270: 1589-95
12. 12. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1983; 84: 1977-83
13. 13. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988; 260: 1910-6
14. 14. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against prophylactic use of lidocine in acute myocardial infarction. Arch Intern Med 1989; 149: 2694-8
15. 15. Echt DS, Liebson PR, Mitchell LB, CAST Investigators, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-8
16. 16. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988; 61: 501-9
17. 17. Cardiac Arrhythmia Supression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33
18. 18. Greene HL, Roden DM, Katz RJ, CAST Investigators, et al. The cardiac arrhythmia suppression trial: first CAST ... then CAST II. J AM Coll Cardiol 1992; 19: 894-8
19. 19. Epstein AE, Hallstrom AP, Rogers WJ, CAST Investigators, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993; 270: 2451-5
20. 20. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7
21. 21. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 1985; 313: 1055-8
22. 22. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 1982; 247: 1707-14
23. 23. International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984; 310: 9-15
24. 24. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. N Engl J Med 1989; 320: 618-27
25. 25. Julian DC, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1: 1142-7
26. 26. Mason JW, Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993; 329: 445-51
27. 27. Mason JW, Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 452-8
28. 28. Waldo AL, Camm AJ, deRuyter H, the SWORD Investigators, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12
29. 29. Sanderson J. The SWORD of Damocles [commentary]. Lancet 1996; 348: 2-3
30. 30. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711-8
31. 31. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056-62
32. 32. Cairns JA, Connolly SJ, Roberts R, Canadian Myocardial Infarction Arrhythmia Trial Investigators, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675-82
33. 33. Julian DG, Camm AJ, Frangin G, European Myocardial Infarct Amiodarone Trial Investigators, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74
34. 34. Held PH, Yusef S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-92
35. 35. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990; 66: 779-85
36. 36. Hansen JF, Danish Study Group on Verapamil in Myocardial Infarction. Treatment with verapamil during and after an acute myocardial infarction: a review based on the danish verapamil infarction trials I and II. J Cardiovasc Pharmacol 1991; 18 Suppl. 6: S20-5
37. 37. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987; 59: 84-94B
38. 38. Yellon DM, Hearse DJ, Maxwell MP, et al. Sustained limitation of myocardial necrosis 24 hours after coronary occlusion: verapamil infusion in dogs with small myocardial infarcts. Am J Cardiol 1983; 51: 1409-13
39. 39. Multicenler Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92
40. 40. Wong SC, Greenberg H, Hager WD, et al. Effects of diltiazem on recurrent myocardial infarction in patients with non-Q wave myocardial infarctions. J Am Coll Cardiol 1992; 19 (7): 1421-5
41. 41. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind randomized, multicenter trial. N Engl J Med 1986; 315 (7): 423-9
42. 42. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40
43. 43. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337: 1569-75
44. 44. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83
45. 45. Buxton AE, Fisher JD, Josephson ME, MUSTT Investigators, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36: 215-26
46. 46. Camm AJ, Fei L. Risk stratification after myocardial infarction. Pacing Clin Electrophysiol 1994; 17: 401-16
47. 47. Deewania PC, Amsterdam EA, Vagelos RH, California Working Group on Post-MI Management. Evidence-based, cost-effective risk stratification and management after myocardial infarction. Arch Int Med 1997; 157: 273-80